1. New Data on the Safety of SGLT2 Inhibitors

3. Program Goals

4. The Newest Antihyperglycemic Class SGLT2 Inhibitors

5. DKA

6. SGLT2 Inhibitor-Induced Euglycemic DKA

7. Euglycemic DKA: Case Studies

8. DKA: Canagliflozin Clinical Program

9. EMPA-REG OUTCOME TRIAL DKA

10. SGLT2 Inhibitor-Induced DKA A Diagnostic Challenge

11. Euglycemic DKA Predictable and Detectable

12. DKA Prevention

13. Bone Fractures A Possible Risk With SGLT2 Inhibitors

14. Bone Fractures with SGLT2 Inhibitors Possible Mechanism?

16. EMPA-REG OUTCOME TRIAL Bone Fractures

17. Clinical Relevance Use of SGLT2 Inhibitors in Older Individuals

19. 2015 AACE/ACE Expert Recommendations: DKA

20. 2015 AACE/ACE Expert Recommendations: DKA (cont)

21. Risk Factors for Recurrent Falls

22. Abbreviations